Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial

[1]  Zhen-wen Liu,et al.  Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation , 2022, Annals of medicine.

[2]  T. Meyer,et al.  Novel Cellular Therapies for Hepatocellular Carcinoma , 2022, Cancers.

[3]  Jiyuan Zhang,et al.  Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC , 2021, Hepatology communications.

[4]  H. Nishikawa,et al.  Engineering strategies for broad application of TCR-T and CAR-T cell therapies. , 2021, International immunology.

[5]  C. Cho,et al.  Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons , 2021, Frontiers in Immunology.

[6]  A. Bertoletti,et al.  Immunosuppressive Drug‐Resistant Armored T‐Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients , 2020, Hepatology.

[7]  S. Colquhoun.  Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies , 2020 .

[8]  F. Ciceri,et al.  TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals , 2020, Frontiers in Immunology.

[9]  A. Bertoletti,et al.  Personalized T-cell therapy in liver transplanted patients with hepatitis B virus related hepatocellular carcinoma , 2020 .

[10]  D. Sinn,et al.  Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data , 2019, BMC Cancer.

[11]  E. Guccione,et al.  Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. , 2019, Gastroenterology.

[12]  S. Knechtle,et al.  The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis , 2018, Clinical transplantation.

[13]  A. Tambur.  Human leukocyte antigen matching in organ transplantation: what we know and how can we make it better (Revisiting the past, improving the future) , 2018, Current opinion in organ transplantation.

[14]  S. Zappavigna,et al.  Hepatocarcinoma: genetic and epigenetic features. , 2018, Minerva gastroenterologica e dietologica.

[15]  Daniel A. Anaya,et al.  Liver Resection and Surgical Strategies for Management of Primary Liver Cancer , 2018, Cancer control : journal of the Moffitt Cancer Center.

[16]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[17]  Mohamad Amin Pourhoseingholi,et al.  Hepatocellular carcinoma in Asia: Prevention strategy and planning. , 2015, World journal of hepatology.

[18]  J. Lee,et al.  Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. , 2015, Gastroenterology.

[19]  A. Bertoletti,et al.  Building and Optimizing a Virus-specific T Cell Receptor Library for Targeted Immunotherapy in Viral Infections , 2014, Scientific Reports.

[20]  D. Campana,et al.  A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.

[21]  S. Strasser,et al.  Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: a multicenter, exploratory analysis. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[22]  Hong-Xia Wang,et al.  Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety , 2012, Experimental Hematology & Oncology.

[23]  U. Neumann,et al.  Impact of human leukocyte antigen matching in liver transplantation , 2003, Transplantation.

[24]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[25]  M. Melcher,et al.  Primary Surgical Resection Versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients , 2013, Digestive Diseases and Sciences.

[26]  J. Stein‐Streilein.  Infection, Immune Homeostasis and Immune Privilege , 2012, Birkhäuser Advances in Infectious Diseases.